Anavex Life Sciences, a small drug maker in New York City, has committed publicly to an ambitious roster of clinical trials for its lead pipeline product Anavex 2-73, including trials in Alzheimer’s, Parkinson’s, and other serious neurological diseases.
But does Anavex have clearance from regulators in the U.S. and Europe to enroll patients in those Anavex trials?
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
Anavex Now is trying to gain access to this potentially life saving drug for ALL AMERICANS! Please follow Anavex Now on Facebook and help us get this miracle drug to market. Oral dosing, safe, healthy side effects(Sleep, etc..) PLEASE HELP US GET THIS AWESOME DRUG TO MARKET..
Maybe should have held this “insight and analysis” a bit longer: https://www.nasdaq.com/press-release/anavex-life-sciences-receives-approval-to-initiate-phase-2-clinical-trial-of-anavex273-for-the-20180709-00270